MLAB (Mesa Laboratories) Current Deferred Revenue: $14.7 Mil (As of Mar. 2026)


MLAB Mesa Laboratories Inc MLAB
77 GF Score
Price $95.61
GF Value $116.24
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Mesa Laboratories Current Deferred Revenue?

Mesa Laboratories MLAB +0.27% 77 Current Deferred Revenue is $14.7 Mil as of Mar. 2026. GuruFocus rates MLAB with a GF Score™ of 77/100 and a GF Value™ of $116.24 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Mesa Laboratories's current deferred revenue for the quarter that ended in Mar. 2026 was $14.7 Mil.

Mesa Laboratories Current Deferred Revenue Related Terms

Mesa Laboratories Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Mesa Laboratories's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesa Laboratories Current Deferred Revenue Chart

Mesa Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.58 15.69 15.48 14.71 14.72

Mesa Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.71 15.08 14.26 14.56 14.72
MLAB
77GF Score
Mesa Laboratories Inc MLAB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $14.7 Mil mean?
Mesa Laboratories (MLAB) has a Current Deferred Revenue of $14.7 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Mesa Laboratories and its competitors.
Is Mesa Laboratories' Current Deferred Revenue too high?
Mesa Laboratories' current Current Deferred Revenue is $14.7 Mil. Overall, Mesa Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mesa Laboratories' Current Deferred Revenue compare to AERG and USBC?
Mesa Laboratories' Current Deferred Revenue of $14.7 Mil can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Hardware company?
A good Current Deferred Revenue depends on the Hardware industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Mesa Laboratories and its competitors. Mesa Laboratories's current Current Deferred Revenue is $14.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Mesa Laboratories (MLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $116.24, compared to a current price of $95.61 — trading 17.7% below its estimated fair value. The current Current Deferred Revenue is $14.7 Mil. Mesa Laboratories' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Mesa Laboratories (MLAB), the current Current Deferred Revenue is $14.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mesa Laboratories (MLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mesa Laboratories stock appears to be undervalued. The current stock price of $95.61 is trading 17.7% below its estimated GF Value™ of $116.24. GuruFocus considers Mesa Laboratories to be Modestly Undervalued.

Key valuation signals for MLAB:

  • Current Deferred Revenue: $14.7 Mil
  • GF Value™: $116.24 vs. price of $95.61 (17.7% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the MLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mesa Laboratories Business Description

Address 12100 West Sixth Avenue, Lakewood, CO, USA, 80228
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
77GF Score

Get the complete analysis for MLAB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$95.61
Price
$116.24
GF Value